08th week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160051646 | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS - Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described. | 2016-02-25 |
20160051647 | CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE - Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals. | 2016-02-25 |
20160051648 | COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA - Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders. | 2016-02-25 |
20160051649 | Vaccine Against Rhipicephalus Ticks - The present invention generally relates to the fields of parasitology and immunology, and especially to a vaccine against | 2016-02-25 |
20160051650 | A CANCER VACCINE FOR CATS - The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof. | 2016-02-25 |
20160051651 | TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR - The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain. | 2016-02-25 |
20160051652 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 2016-02-25 |
20160051653 | TUMOR VACCINATION IN COMBINATION WITH HEMATOPOIETIC CELL TRANSPLANTATION FOR CANCER THERAPY - In one aspect, the present invention provides a method for treating cancer comprising tumor cell vaccination in combination with hematopoietic and immune cell transplantation. In some embodiments, the method involves autologous tumor cell vaccination prior to autologous hematopoietic and immune cell transplantation. In another aspect, the present invention provides a method of purifying tumor cells from a subject in preparation for vaccination. | 2016-02-25 |
20160051654 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 2016-02-25 |
20160051655 | YERSINIA SPP. POLYPEPTIDES AND METHODS OF USE - The present invention provides isolated polypeptides isolatable from a | 2016-02-25 |
20160051656 | BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE | 2016-02-25 |
20160051657 | Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias - The invention relates to vaccines for treating prostate inflammation and benign prostate hyperplasias (stages I and II) comprising | 2016-02-25 |
20160051658 | NEISSERIAL ANTIGENIC PEPTIDES - This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria | 2016-02-25 |
20160051659 | Gene optimized hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome - A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any | 2016-02-25 |
20160051660 | METHODS OF PRODUCING INFLUENZA VACCINE COMPOSITIONS - Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided. | 2016-02-25 |
20160051661 | FLUOROCARBON-LINKED PEPTIDE FORMULATION - The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles. | 2016-02-25 |
20160051662 | H3 INFLUENZA A VIRUS - The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. | 2016-02-25 |
20160051663 | METHODS AND DEVICES FOR CANINE HERPESVIRUS 1 (CHV-1) DETECTION AND PREVENTION - Methods for detection of canine herpes virus 1 (CHV-1) in archived paraffin-embedded tissue are provided. The methods use CHV-1 glycoprotein B (gB)-specific PCR to detect the CHV-1. A vaginal sleeve that protects puppies from contracting CHV-1 by contact with the mother's vaginal wall during birth is also provided. The sleeve is inserted into the vagina of a pregnant female dog prior to birth and puppies traverse the birth canal through the sleeve without coming into direct contact with vaginal tissue. Compositions and methods of immunizing against CHV-1 in dogs of all ages are also provided. | 2016-02-25 |
20160051664 | RECOMBINANT POLYNUCLEOTIDE AND A TRANSGENIC FLAMMULINA VELUTIPES CARRYING THE SAME - The invention provides a recombinant polynucleotide comprising a truncated glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter and a modified HBV S protein gene and a transgenic | 2016-02-25 |
20160051665 | INDUCTION OF IMMUNE RESPONSE - Provided are methods and compositions that can be used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, DNA constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue. | 2016-02-25 |
20160051666 | Novel Prostate Kallikrein Allergen - Methods for treatment of a Type I allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its IgE binding response. Diagnostic kits comprise the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support. | 2016-02-25 |
20160051667 | CONJUGATION OF STAPHYLOCOCCUS AUREUS TYPE 8 CAPSULAR POLYSACCHARIDES - The invention provides a process for preparing a conjugate of a | 2016-02-25 |
20160051668 | METHODS FOR IMPROVING IMMUNOLOGICAL RESPONSE IN VACCINATED ANIMALS - A method is provided for increasing an immunological response to a target antigen in an animal by administering an immunogenic amount of a vaccine comprising a polypeptide conjugate comprising the target antigen conjugated to a carrier polypeptide by means of a linker polypeptide which is rich in predicted linear B-cell epitopes. | 2016-02-25 |
20160051669 | COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING TREGS - It has been discovered that PIK3δ (PIK3delta) selectively modulates the activation and proliferation of natural Tregs. Methods of modulating immune responses by modulating PIK3δ bioavailability or biological activity are provided. | 2016-02-25 |
20160051670 | METHODS FOR PREPARING SQUALENE - An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature T | 2016-02-25 |
20160051671 | COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE - The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases. | 2016-02-25 |
20160051672 | METHODS OF TREATMENT WITH ANTAGONISTS AGAINST PD-1 AND PD-L1 IN COMBINATION WITH RADIATION THERAPY - This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist, wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later. | 2016-02-25 |
20160051673 | COMPOSITIONS AND METHODS FOR INCREASING THE SERUM HALF-LIFE OF A THERAPEUTIC AGENT TARGETING COMPLEMENT C5 - The disclosure features compositions and methods for increasing the half-life of a therapeutic agent (e.g., a C5 antagonist) in the serum of a subject (e.g., a human). Also featured are compositions and methods for: (i) decreasing the frequency by which a therapeutically effective amount of a therapeutic agent must be administered to a human having, suspected of having, or at risk for developing, a medical condition for which the therapeutic agent is effective and (ii) decreasing the dosage of the therapeutic agent required for therapeutic efficacy in a human having, suspected of having, or at risk for developing, a medical condition for which the therapeutic agent is effective. The methods include reducing the serum concentration of the antigen to which the therapeutic agent binds. | 2016-02-25 |
20160051674 | METHODS AND PHARMACEUTICAL COMPOSITIONS (CTPS 1 INHIBITORS, E.G. NORLEUCINE) FOR INHIBITING T CELL PROLIFERATION IN A SUBJECT IN NEED THEREOF - The present invention relates to methods and pharmaceutical compositions for inhibiting lymphocyte proliferationin a subject in need thereof. In particular, the invention relates to a CTP synthase 1 (CTPS1) inhibitor for use in a method for inhibiting lymphocyte proliferationin a subject in need thereof. The invention also relates to a method for screening a plurality of test substances useful for inhibiting lymphocyte proliferationin a subject in need thereof comprising the steps consisting of i) testing each of the test substances for its ability to inhibit CTPS1 activity or expression and ii) identifying the test substance which inhibits CTPS1 activity or expression thereby to identify a test substance useful for inhibiting lymphocyte proliferationin a subject in need thereof. | 2016-02-25 |
20160051675 | B7-H4 EXPRESSION ON TUMOR VASCULATURE - Methods of evaluating patients by assessing expression of B7-H4 in the vasculature are described. | 2016-02-25 |
20160051676 | TRANSITION METAL PORPHYRIN COMPLEXES AND METHODS OF TREATMENT USING SAME - A porphyrin of general formula (I) having a transition metal (II) cation in its core and one or two mono-, di-, tri-, tetra- or penta-halophenyl groups and two or three pyridyl groups in the 5, 10, and/or 15 positions of the porphyrin ring contributing to a positive two or three charge neutralized by the presence of a respective number of anions. The porphyrin of the general formula (I) characterized by killing | 2016-02-25 |
20160051677 | PROCESS FOR PURIFYING RECOMBINANT PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN - The present invention relates to processes for purifying high-quality recombinant | 2016-02-25 |
20160051678 | SUSPENSION PHARMACEUTICAL FORMULATIONS COMPRISING LOW MELTING PROPIONIC ACID DERIVATIVE PARTICLES - Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed. | 2016-02-25 |
20160051679 | Pemetrexed Formulation - The invention provides stable formulations of pemetrexed for infusion. The formulations are based on using pemetrexed diacid and certain selected suitable stabilising basic amine compounds that provide counter ions to the pemetrexed diacid, forming base addition salts. The formulations can be dried powder formulations to be reconstituted as liquid concentrate formulations or directly in ready-to-use infusion solutions, or they can be liquid formulations, most suitably concentrates to be diluted in infusion solution prior to use. The suitable basic amine addition compounds according to the invention are one or more of diethanolamine, tris-(hydroxymethyl)aminomethane and meglumine. | 2016-02-25 |
20160051680 | Co-Processed Carbohydrate System as a Quick-Dissolve Matrix for Solid Dosage Forms - The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly and completely dissolve or disintegrate in the oral cavity within 60 seconds. The invention also comprises the solid dosage forms produced by directly compressing the co-processed carbohydrate system, some of which, when placed in the oral cavity, shall dissolve or disintegrate, preferably within about 60 seconds. | 2016-02-25 |
20160051681 | Transdermal Pharmaceutical Bases for Treating Ear Disorders - The present disclosure refers to transdermal pharmaceutical bases that include a synergistic combination of a silicone base with a natural permeation enhancement composition (NPE). Further, these transdermal pharmaceutical bases are proposed to treat ear diseases in mammals The silicone base includes silicone, pracaxi oil, and seje oil. Additionally, the NPE composition includes one or more phospholipids, one or more oils rich in essential fatty acids, behenic acid, and oleic acid, one or more skin lipids, and one or more butters rich in linoleic acid and linolenic acid. The synergistic combination of aforementioned natural components exhibit enhanced healing properties, thereby providing organic acids with antioxidant, antibacterial, and antifungal properties. The transdermal pharmaceutical bases are employed to increase the residence time of the medicament in the ear canal, and increase the penetration of the APIs into the affected area, thereby enhancing treatment effectiveness. | 2016-02-25 |
20160051682 | COMPOSITION AS AUXILIARY MEANS FOR ORAL MEDICATION - The invention relates in one aspect to acomposition, specifically a jelly, the use of which composition as an auxiliary means is to ease the taking of oral medication in solid form, which composition comprises iota-carrageenan as a jellifying agent and citric acid as a salivating agent, characterized in that the composition further comprises maltodextrin. In another aspect, the composition comprises a calcium sequestrant for adjusting Ca-ion activity of the composition. In one embodiment, the composition comprises iota-carrageenan in 0.7-1.0% in mass, citric acid in 0.06-0.07% in mass, maltodextrin in 1.5% in mass, all relative to the total mass of the composition, and an amount of a calcium sequestrant such that the Ca-ion activity of the composition is between 20 ppm and 80 ppm. | 2016-02-25 |
20160051683 | EXCIPIENT COMPOSITIONS FOR MUCOADHESIVE PHARMACEUTICAL COMPOSITIONS INCLUDING A SYNERGISTIC COMBINATION OF AMYLOPECTIN, PULLULAN, HYALURONIC ACID, AND XYLOGLUCAN - Excipient compositions including a combination of excipients for mucoadhesive pharmaceutical compositions that improve mucoadhesiveness power, as well as release of and adhesion time of suitable active pharmaceutical ingredients (APIs) are disclosed. The excipient compositions include an aqueous solution with a synergistic combination of polymers, such as, for example amylopectin, pullulan, hyaluronic acid, and tamarind xyloglucan, among others. These polymers have been demonstrated to improve the release of as well as the adhesion time of APIs onto mucosa membrane. Mucoadhesive pharmaceutical compositions that include excipient compositions include suitable APIs, such as, for example analgesics, anesthetics, anthelmintics, anti-allergic agents, anti-fungals, antihistamines, anti-inflammatory agents, antimigraine agents, and hormones, among others. Mucoadhesive pharmaceutical compositions including excipient compositions are employed in the treatment of a plurality of mucous membrane diseases. | 2016-02-25 |
20160051684 | Natural Suspending Agent Including a Synergistic Blend of Xanthan Gum and Konjac Powder for Oral Pharmaceutical Suspensions - The present disclosure refers to a synergistic blend of Konjac powder and Xanthan gum that is included, as a natural suspending agent, in oral pharmaceutical suspensions. Oral pharmaceutical suspensions comprising the synergistic blend are aqueous solutions. The synergistic blend, used as a suspension agent to suspend suitable active pharmaceutical ingredients (APIs), improves the stability of oral pharmaceutical suspensions, and helps in the formation of a thermo-reversible gel and shear thinning necessary to keep APIs suspended within oral pharmaceutical suspensions. The synergistic blend of Konjac powder and Xanthan gum has unique anti-flocculation properties, which improve the homogeneity of the oral pharmaceutical suspensions. Additionally, the blend provides a better texture and mouth feel. Oral pharmaceutical suspensions, comprising the synergistic blend, include a vehicle, such as water, as well as different components, such as, for example APIs, preservatives, sweeteners, flavoring agents, and pH regulators or buffers, among others. | 2016-02-25 |
20160051685 | 5a-Androstane-3 ,5,6 -Triol Injection and Preparation Method Theref48 - A 5α-androstane-3β,5,6β-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-β-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-β-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-β-cyclodextrin solution, 5α-androstane-3β,5,6β-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection. Drying the filtrate yields a solid for injection. | 2016-02-25 |
20160051686 | Pharmaceutical Compositions for Treating Ear Diseases - The present disclosure relates to pharmaceutical compositions with increased skin permeability for treating ear disease in mammals Disclosed pharmaceutical compositions are prepared as topical gels or as transdermal gels. The pharmaceutical compositions reduce ear inflammation and irritation produced by ear diseases or injuries (e.g., cauliflower ear, chronic otitis, and the like). The pharmaceutical compositions include a synergistic combination of pracaxi oil and seje oil. Additionally, the pharmaceutical compositions include phosphatidylcholine as a permeation enhancer. The combination of aforementioned natural components exhibits enhanced healing properties, thereby providing organic acids with antioxidant, antibacterial, and antifungal properties. The synergistic combination of pracaxi and seje oil increases the skin permeability to active pharmaceutical ingredients (APIs), thereby passing through the stratum corneum and reaching the target area; therefore, the dosage and time of treatment is significantly reduced. | 2016-02-25 |
20160051687 | BACTERIALLY-DERIVED, INTACT MINICELLS THAT ENCOMPASS PLASMID-FREE FUNCTIONAL NUCLEIC ACID FOR IN VIVO DELIVERY TO MAMMALIAN CELLS - Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation. | 2016-02-25 |
20160051688 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY - Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention. | 2016-02-25 |
20160051689 | SUPRAMOLECULAR AGGREGATES COMPRISING MALEIMIDO CORES - The invention relates to a supramolecular aggregate of formula (VI) wherein A is an active substance, and X | 2016-02-25 |
20160051690 | METHODS FOR THE DEVELOPMENT OF VACCINES BASED ON OLIGOSACCHARIDE-OLIGONUCLEOTIDE CONJUGATES - Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through an iterative screening process. | 2016-02-25 |
20160051691 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES - The present invention provides iRNA agents comprising at least one subunit of the formula (I): | 2016-02-25 |
20160051692 | NOVEL METHODS OF USE OF BIOMIMETIC PROTEOGLYCANS - In one aspect, the present invention relates to a new method of treating or preventing urinary incontinence in a mammal in need thereof. In certain embodiments, the method comprises contacting a composition comprising at least one biomimetic proteoglycan with the urethral or periurethral tissue of the mammal. | 2016-02-25 |
20160051693 | Cellular Delivery of DNA Intercalating Agents - Compositions and methods for targeted delivery of active agents to cells are provided. The compositions comprise a wholly or partially double-stranded synthetic DNA carrier, and an active agent intercalated in double-stranded portions of the DNA carrier. The DNA carrier may also be linked to a targeting agent. The compositions are useful for delivering an active agent into a targeted cell type, for example a cytotoxic agent. | 2016-02-25 |
20160051694 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS - Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer. | 2016-02-25 |
20160051695 | HER2 ANTIBODY-DRUG CONJUGATES - The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleaved under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker. In some aspects of the present disclosure, the targeting moiety is an anti-HER2 antibody. The present disclosure further provides compositions and methods for treating cancers. | 2016-02-25 |
20160051696 | POLYPEPTIDE COMPLEX COMPRISING NON-PEPTIDYL POLYMER HAVING THREE FUNCTIONAL ENDS - Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified. | 2016-02-25 |
20160051697 | NANODELIVERY DEVICE FOR THERAPEUTIC LOADING OF CIRCULATING ERYTHROCYTES - According to one embodiment, a person's own RBCs can be recruited as secondary bioscavenger carriers in vivo using a nanopolymer-BChE complex, with an affinity ligand (antibody or peptide) for selective targeting to the RBCs and a cell-penetrating peptide for uptake into the RBCs. A general approach according to an embodiment involves parenteral administration of the nanodevice to gain access to the systemic circulation, which then seeks out and attaches to the person's RBCs, followed by transport into the RBCs (to minimize clearance from the circulation), leading to long-term circulation of the bioscavenger enzymes and thus protection against intoxication. | 2016-02-25 |
20160051698 | Nanoscale Artificial Antigen Presenting Cells - This disclosure provides nano-scale Artificial Antigen Presenting Cells (aAPC), which deliver stimulatory signals to lymphocytes, including cytotoxic lymphocytes, for use as a powerful tool for immunotherapy. | 2016-02-25 |
20160051699 | GENE THERAPY FOR NEURODEGENERATIVE DISORDERS - Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed. | 2016-02-25 |
20160051700 | SYSTEMS AND METHODS FOR THE TARGETED PRODUCTION OF A THERAPEUTIC PROTEIN WITHIN A TARGET CELL - Provided are nucleic acid-based expression constructs for the targeted production of a therapeutic protein within a cell that is associated with aging, disease, another condition. Also provided are vectors and systems for the delivery of those nucleic acid-based expression constructs as well as methods for using such nucleic acid-based expression constructs, vectors, and systems for reducing, preventing, and/or eliminating the growth and/or survival of an age-, disease-, or condition-associated cell and for the treatment of a disease or condition that is associated with an age, disease, or condition associated cell. | 2016-02-25 |
20160051701 | IMPROVED METHODS FOR OSTEOARTHRITIS THERAPY - The present invention provides improved methods for osteoarthritis therapy. In particular, the present invention provides a method for predicting the responsiveness of a subject to cell therapy for osteoarthritis comprising administering to the subject platelet-rich plasma (PRP) and assessing pain and/or mobility, wherein a decrease in pain and/or an increase in mobility indicates that the subject will be responsive to cell therapy. | 2016-02-25 |
20160051702 | SYSTEMS AND METHODS FOR PRECLINICAL MODELS OF METASTASES - Embodiments of the invention provide methods of creating clinical models for different forms of metastatic cancer. The methods may include obtaining samples from subjects with metastatic cancer, determining an allelic status of one or more markers in the samples (e.g., creating a molecular profile of the subject's cancer), and using model organisms with subject-derived xenografts for treatment selection. | 2016-02-25 |
20160051703 | METHODS AND COMPOSITIONS FOR IMPROVING SLEEP AND MEMORY - A method for determining whether a substance can increase the expression level of a fatty acid binding protein (FABP) in an animal. The method includes using a cell that includes an expression construct that comprises a FABP promoter operably linked to a polynucleotide sequence encoding a reporter molecule, wherein the cell is contacted with a candidate substance and then cultivating the cell under conditions conducive to expression of the reporter molecule. Increased expression of the construct in the presence of the candidate substance as compared to a control leads to improved sleep and long-term memory in the subject. | 2016-02-25 |
20160051704 | MOLECULAR IMAGING PROBES FOR LUNG CANCER INTRAOPERATIVE GUIDANCE - Molecular probes directed to the delta opioid receptor and associated methods of use as non-invasive diagnostics for lung cancer are presented. The molecular probes generally consist of a ligand (Dmt-Tic) that is conjugated to a detection moiety such as a fluorescent dye or a radionuclide by a linker molecule. Once the probe is administered, it may be detected by a molecular imaging device to locate tumors for treatment or removal. Also presented are novel markers for lung cancer including, but not limited to, CA9, CA12, CTAG2, CXorf61, DSG3, FAT2, KISS1R, GPR87, LYPD3, OPRD1, SLC7A11 and TMPRSS4. Probes may be developed that can target these cell surface markers. | 2016-02-25 |
20160051705 | FUNCTIONALIZATION OF AND USE OF FUNCTIONALIZED SECOND HARMONIC GENERATING NANOPROBES - Functionalized second harmonic nanoprobes for imaging samples and a method of using such probes to monitor the dynamics different processes using a variety of imaging techniques are provided. The functionalized second harmonic generating (SHG) nanoprobes are comprised of various kinds of nanocrystalline materials that do not possess an inversion symmetry and therefore are capable of generating second harmonic signals that can then be detected by conventional two-photon microscopy, and are provided with functional surface modifications that allow for targeted imaging of a variety of biological and non-biological processes and structures such as cell signaling, neuroimaging, protein conformation probing, DNA conformation probing, gene transcription, virus infection and replication in cells, protein dynamics, tumor imaging and cancer therapy evaluation and diagnosis as well as quantification in optical imaging. | 2016-02-25 |
20160051706 | PROCESS FOR PRODUCING A COMPLEX OF A LANTHANIDE WITH A MACROCYCLIC LIGAND - A process for producing a complex of a lanthanide or similar compound with a macrocyclic ligand, wherein the ratio of macrocyclic ligand in free form in relation to the lanthanide or similar compound is equal or more than 0.002% mol/mol, includes the steps of a) measuring the moisture content in a sample of the macrocyclic ligand; and b) mixing an amount G of the lanthanide with an amount X3 of the macrocyclic ligand with the proviso that X3=LG+Lf+M, wherein LG is the amount of macrocyclic ligand necessary for complexing the amount G of lanthanide or similar compound, Lf is an excess amount of the macrocyclic ligand, and M is the amount of moisture present in the amount X3 of the macrocyclic ligand. | 2016-02-25 |
20160051707 | Metal Oxide Nanoparticle-Based T1-T2 Dual-Mode Magnetic Resonance Imaging Contrast Agent - The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion. | 2016-02-25 |
20160051708 | Metal Oxide Nanoparticle-Based Magnetic Resonance Imaging Contrast Agent with a Central Cavity - The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MRI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis. | 2016-02-25 |
20160051709 | COMPOSITION-CONTROLLED NOBLE METAL-TRANSITION METAL SMALL NANOPARTICLE ALLOYS WITH NIR-EMISSION AND HIGH T2 RELAXIVITY AND METHOD FOR MAKING SAME - A method for producing small nanoparticles of a discrete noble metal-transition metal nanoparticle alloy, comprising: mixing, at room temperature in air, a first aqueous solution having a first molar ratio of a noble metal and a transition metal with an organic ligand and a reducing agent. A method for producing small nanoparticles of a discrete gold-cobalt nanoparticle alloy, comprising: mixing, at room temperature in air, a first aqueous solution having a first molar ratio of HAuCl | 2016-02-25 |
20160051710 | Radiolabelling Process - The present invention relates to a novel composition comprising 1-amino-3[ | 2016-02-25 |
20160051711 | COMPOUND SUITABLE FOR DETECTION OF VESICULAR ACETYLCHOLINE TRANSPORTER - The present invention provides a compound represented by formula (I), wherein in formula (I), R | 2016-02-25 |
20160051712 | Method and Device for Generating a Sterile Area for an Operation, Examination or Treatment of an Object, in Particular of a Person - The invention relates to a method for generating a sterile area for an operation, examination or treatment of at least a partial area of an object, in particular of a person, in which method cold plasma gas is emitted into the area by at least one plasma generator. The invention further relates to a device for carrying out such a method. | 2016-02-25 |
20160051713 | Fixture Sanitizer - A sanitizer for sanitizing various plumbing fixtures and specifically, to a chemical-free sanitizer, more specifically to an ozone-free sanitizer, and yet more specifically to an electronic sanitizer using ions. | 2016-02-25 |
20160051714 | APPARATUS FOR FUMIGATING WITH CHLORINE PEROXIDE GAS AND METHOD THEREFOR - Disclosed is an apparatus and a method for fumigation using chlorine dioxide. The apparatus for fumigation using chlorine dioxide includes: a supply part configured to supply the chlorine dioxide; a gas sensor configured to sense the chlorine dioxide in a target space into which mixed gas including the chlorine dioxide is injected; an introduction part configured to introduce dilution gas for diluting the chlorine dioxide; a mixing part connected to the supply part and the introduction part, and configured to generate the mixed gas by mixing the dilution gas with the chlorine dioxide according to information on a concentration of the chlorine dioxide output from the gas sensor so that the concentration of the chlorine dioxide in the target space may be located within a preset actual concentration band; and a transfer part connected to the mixing part to transfer the mixed gas to the target space. | 2016-02-25 |
20160051715 | DECONTAMINATION SYSTEM - A system for decontaminating an enclosed area includes a reservoir containing a disinfectant solution therein. One or more pumps are in fluid communication with the reservoir. One or more ports are operatively connected to the reservoir or operatively connected to an enclosed area to be decontaminated or operatively connected to the reservoir and to an enclosed area to be decontaminated. One or more connector assemblies are removably attachable to the one or more ports to provide fluid flow communication between the disinfectant solution source and the enclosure to be decontaminated. | 2016-02-25 |
20160051716 | THERMALLY EFFICIENT PORTABLE VAPORIZER HEATING ASSEMBLY - A portable hand-held vaporizer assembly having a glass body defining an airflow passage is disclosed. A heating element is thermally coupled to the glass body and a material placement zone is downstream from the airflow passage. Furthermore, a thermally conductive layer covers at least a portion of an outer surface of the glass body and a thermally reflective substance is included with walls encapsulating the glass body and the heating element. | 2016-02-25 |
20160051717 | MOBILE DEVICE HOLDER AND AIR FRESHENER - Technologies are generally described for systems, devices and methods relating to a mobile device holder and air freshener. The mobile device holder and air freshener may include a body, a fastening component, and a removable cap. The body may be arranged so as to include an interior that is at least partially hollow. The fastening component may be effective to secure a mobile electronic device to the device. The removable cap may include a first vent effective to allow air to flow into or out of the device. The removable cap may allow scented material to be installed within the mobile device holder and air freshener. The body may be further arranged so as to allow air that has entered the device through the first vent to become scented and flow out of the device through the first vent or a second vent included in the body of the device. | 2016-02-25 |
20160051718 | Gel Can Air Freshener with Dual Scent - An air freshener comprises a container divided into separate and discrete reservoirs separated by an inner wall. A cap is disposed on the container and covers the reservoirs. First and second different fragrant materials are each disposed in a different one of the separate and discrete reservoirs so that the first and second different fragrant materials are separate and discrete with respect to one another in the container. The first and second different fragrant materials have different fragrances combinable in a synergistic manner. The first and second different fragrant materials each comprise a water based gel. One of the fragrant materials can comprise a neutralizing agent. | 2016-02-25 |
20160051719 | AIR CLEANING DEVICE, AIR CLEANING METHOD USING THE AIR CLEANING DEVICE, AND AIR CLEANING SYSTEM - To provide an illuminating device-cum-air cleaning device that solves a heat problem and allows efficient operation of an air cleaning means. | 2016-02-25 |
20160051720 | MICROBICIDAL COMPOSITE MATERIAL - A composite material having inherent microbicidal activity is herewith described. The microbicidal composite material comprises of a first layer having a first predefined thickness and a first predefined stitch/thread density; a second layer having a second predefined thickness and a second predefined stitch/thread density; an intermediate layer having a third predefined thickness and a third predefined stitch/thread density, wherein the intermediate layer is sandwiched between the first layer and the second layer, and where the intermediate layer is connected to the first layer and the second layer to form a three dimensional structure, and where each layer in the three dimensional structure has a plurality of apertures. Further, at least one layer in the three dimensional structure comprises at least one of microfibers and nanofibres having augmented surface moieties, wherein the augmented surface moieties allow for binding of a microbicidal agent to impart the inherent microbicidal activity. | 2016-02-25 |
20160051721 | BIOABSORBABLE POLYMERS - A new material was assessed in a patellar reattachment model in sheep and evaluated using histology and biomechanical testing. Overall, these materials showed they produced minimal reactivity histologically. The new material had higher failure strength overall compared to a previous study with the control material as repairs completed with PLG/CS/TCP anchors were significantly stronger compared to repairs with PLLA anchors. | 2016-02-25 |
20160051722 | Mesenchymal Stem Cell-Hydrogel-Biodegradable or Mesenchymal Stem Cell-Hydrogel-Undegradable Support Composition for Skin Regeneration or Wound Healing - The present invention relates to a composition comprising mesenchymal stem cell-hydrogel-biodegradable support or mesenchymal stem cell-hydrogel-undegradable support, a sheet comprising the composition and a method for the preparation thereof. By using the sheet comprising the adipose-derived mesenchymal stem cell-hydrogel biodegradable or undegradable support, stem cells of high activity may be applied directly to the wound without isolation process using protease. The sheet has extracellular matrices such as collagen, laminin, fibronectin and elastin secreted by stem cells in the culture stage and included completely in the hydrogel, and therefore it has superior skin regeneration and wound healing effects compared with conventional pharmaceutical preparations and shortens therapeutic period. | 2016-02-25 |
20160051723 | BIORESORBABLE TISSUE REPAIR COMPOSITION - Compositions including hyaluronic acid or derivative thereof, a borate containing crosslinking agent, a di or polyvalent metal ion, and, optionally, one or more of N-hydroxysuccinimide, and/or a cationic monomer, oligomer, or polymer selected from the group consisting of hydroxylysine, poly(N-methylethylamine), ε-poly-lysine, or polyamine, or a combination thereof are described. Also, methods for making a bioresorbable tissue repair composition and methods of correcting, sealing, connecting or repairing tissue by contacting the tissue with the bioresorbable tissue repair composition are described. | 2016-02-25 |
20160051724 | POLYMER BASED HYDROGEL - The present invention relates to an anti-aging antimicrobial wound healing polymer based hydrogel. In the study of the present invention, a wound healing gel formulation is developed by combining poloxamer polymers and boron component at adequate concentrations in a carbopol based gel. The said gel exhibits fast action on the damaged area and prevents scar formation. | 2016-02-25 |
20160051725 | BONE GRAFT COMPOSITION AND PREPARATION METHOD THEREOF - The present invention relates to a bone graft composition and a preparation method thereof, and more particularly to bone graft composition having excellent physical properties, which comprises a hydrogel comprising a combination of specific amounts of poloxamer and HPMC, and calcium phosphate compound particles, and a preparation method thereof. | 2016-02-25 |
20160051726 | Collagenous Foam Materials - Provided is a foam material, comprising a plurality of substantially collagenous beads, wherein the foam material is a bead foam, and wherein adjacent collagenous beads are fused together by a network of collagen fibres. Also provided are methods for preparation of foam materials comprising a plurality of substantially collagenous beads. The foam materials may be used in applications such as bioscaffolds for wound healing, soft tissue regeneration and augmentation, for localized cell delivery, or as cell culture substrates for research. The foam materials include natural collagen fibrils that provide a stable scaffold and enhance integration of the implanted scaffold and regeneration of cells and tissue. | 2016-02-25 |
20160051727 | IMPROVEMENTS IN AND RELATING TO COLLAGEN BASED MATERIALS - There are provided collagen based polymeric materials comprising collagen molecules and/or collagen derived molecules which have been functionalised by the addition of one or more ethylenically unsaturated moieties and which have been cross-linked via said moieties. Also provided are collagen based compositions and methods of producing collagen based polymeric materials. | 2016-02-25 |
20160051728 | Decellularized Adipose Tissue - This invention provides a method for decellularizing adipose tissue, comprising subjecting the adipose tissue to one or more incubations in an enzymatic digestion solution containing one or more enzymes, and one or more solvent extractions, wherein decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional structure is obtained. The invention also provides a decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional architecture, and bioscaffolds, microcarrier beads, and coatings comprising the decellularized adipose tissue. | 2016-02-25 |
20160051729 | Reparative Cell Isolation and Delviery - Methods are described for generating autologous tissue grafts, including generating grafts at the point of care, which include isolated cell populations that are enriched with stem cells and are mixed with biological fillers including hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft. | 2016-02-25 |
20160051730 | PLACENTAL TISSUE GRAFTS PRODUCED BY CHEMICAL DEHYDRATION/FREEZE-DRYING AND METHODS FOR MAKING AND USING THE SAME - Described herein are placental tissue grafts produced by chemical dehydration followed by freeze-drying the placental tissue to produce the tissue graft. The tissue grafts retain their biological properties preferably at the same level as the placental tissues before they are processed. The placental tissue grafts have numerous medical applications. Methods for making the tissue graft compositions are also described herein. | 2016-02-25 |
20160051731 | HYBRID GEL COMPRISING PARTICULATE DECELLULARIZED TISSUE - A hybrid gel comprising a particulate decellularized tissue (obtained by pulverizing animal-derived biological tissues that are decellularized (decellularized biological tissues)), fibrinogen and thrombin; a cell culture material comprising the hybrid gel; a method for preparing the hybrid gel; and a kit comprising a particulate decellularized tissue and a biological tissue adhesive are provided. The hybrid gel of the present invention exerts the effect to promote differentiation and gain of function of stem cells and the therapeutic effect to a variety of diseases. | 2016-02-25 |
20160051732 | SHAPEABLE BONE GRAFT SUBSTITUTE AND INSTRUMENTS FOR DELIVERY THEREOF - Injectable bone graft material having a biocompatible, resorbable polymer and a biocompatible, resorbable inorganic material exhibiting macro, meso, and microporosities. | 2016-02-25 |
20160051733 | Coated Vaso-Occlusive Device for Treatment of Aneurysms - A method is described herein for the treatment of intracranial aneurysms. The method comprises inserting into an aneurysm an embolism coil coated with a polymeric coating comprising a genipin, such as genipin or a derivative thereof, thereby increasing the stability of clots within the aneurysm. According to one example, the coating is a poly(L-lactide-co-glycolide) (PLGA) is used to release genipin to crosslink fibrin clots thereby creating more stable occlusions. Increased clotting can improve segregation of the weakened portion of the blood vessel from the rest of the vasculature and reduce the risk of recurrence. | 2016-02-25 |
20160051734 | INWARDLY HYDROPHILICALLY COATED MEDICINAL-TECHNICAL DEVICE - A method for coating a hollow body on its inner surface comprises pre-coating the inner surface with a reactive gas plasma (PECVD), and follow-up-coating the pre-coated surface with a reactive gas component without plasma action (CVD). The resulting hollow body is used for temporarily accommodating bodily liquids, in particular blood, or cell suspensions, due to its hydrophilizing PECVD/CVD-coating on its inner surface. | 2016-02-25 |
20160051735 | Materials, Systems, Devices, And Methods For Endoluminal Electropolymeric Paving And Sealing - Methods, materials, devices, and systems for electropolymeric paving and sealing (ePEPS) are provided. The methods include delivering paving materials to an interior surface of a blood vessel, tissue lumen or other hollow space, delivering electronic components to the surface, and forming a conformal device that contains the paving material and the integrated electronic components. Integrated electronic components can be homogenously or heterogeneously distributed in the material, such as on the top, middle, and/or bottom of the polymeric material. The devices are biocompatible, and preferably biodegradable or bioerodible. The devices integrated electrical properties useful for sensing or detecting one or more analytes, signals or conditions, transmitting or generating a signal, or releasing a therapeutic, prophylactic or diagnostic agent. Optionally, the devices are smart devices that include feedback and logic means to respond to a change in local conditions. | 2016-02-25 |
20160051736 | WOUND TREATMENT APPARATUS - A bandage has a first sheet overlying a wound and located adjacent to it and a top sheet overlying the first sheet. The first sheet has a plurality of discrete passageways overlying the wound and adapted to communicate negative pressure established by a negative pressure source to the wound. | 2016-02-25 |
20160051737 | DEVICE AND METHOD FOR WOUND THERAPY - A wound therapy device is disclosed. The wound therapy device may include a housing for covering at least a portion of a wound and for sealing to a body surface of a patient. The housing may also include a liquid collector for retaining liquid therein and a vacuum connection for coupling to a vacuum source. The vacuum connection may be in gaseous communication with the liquid collector. The vacuum connection may be separated from the liquid collector by a liquid barrier. | 2016-02-25 |
20160051738 | VENTRICULAR CUFF - In one general aspect, a cuff for attachment to a heart includes an attachment component configured to engage a blood pump to attach the cuff to the blood pump and a sewing ring for attachment to the heart. The sewing ring is coupled to the attachment component, and the attachment component and the sewing ring each define a central opening configured to admit an inflow cannula of a blood pump. The sewing ring comprises a member that provides rigidity to flatten a portion of a myocardium of the heart when the cuff is attached to the heart. | 2016-02-25 |
20160051739 | BLOOD PUMP - A blood pump comprising a cartridge, the cartridge comprising a first recess therein, said first recess having a surface, and a flexible diaphragm closing said first recess, the first recess and the flexible diaphragm defining a first pump chamber, said first pump chamber having an inlet and an outlet wherein the flexible diaphragm of the first pump chamber is movable between a first position, separated in use from the surface of the first recess, in which said first pump chamber has a maximum volume, and a second position, substantially adjacent to the surface of the first recess, in which said first pump chamber has a minimum volume a pump driver arranged to interface with the cartridge, said pump driver operable to move the flexible diaphragm of the first pump chamber in a first direction into said first recess to, in use, pump blood from the chamber and to move the flexible diaphragm of the first pump chamber in a second direction away from the first recess to, in use, draw blood into said first pump chamber, wherein the pump driver controls the movement of the flexible diaphragm of the first pump chamber such that the flexible diaphragm of the first pump chamber moves toward said first position at a first speed and moves toward said second position at a second speed, said second speed being greater than said first speed. | 2016-02-25 |
20160051740 | Magnet-Based Systems And Methods For Transferring Fluid - A system is provided for pumping fluid, with the system including a fluid pump and a cassette. The pump includes a motor and a piston that is movable toward and away from a flexible diaphragm of the cassette. A linkage connects the motor and the piston to move the piston toward and away from the diaphragm. At least a portion of the piston or the diaphragm is magnetized, with the other having at least a portion that is magnetized or formed of a ferromagnetic material, thereby magnetically coupling the piston and the diaphragm such that movement of the piston moves the diaphragm into and out of a cassette cavity aligned with the diaphragm and piston. Movement of the diaphragm into and out of the cavity changes the effective volume of the cavity, which has the effect of drawing fluid into or forcing fluid out of the cavity. | 2016-02-25 |
20160051741 | RENAL PUMP - Apparatus and methods are described including identifying a subject as suffering from a condition selected from the group consisting of: cardiac dysfunction, congestive heart failure, reduced renal blood flow, increased renal vascular resistance, arterial hypertension, and kidney dysfunction. In response thereto, blood pressure within a renal vein of the subject is reduced, by placing a blood pump inside the subject's renal vein and activating the impeller to pump blood from the renal vein into the subject's vena cava. Other applications are also described. | 2016-02-25 |
20160051742 | SYSTEM FOR IDENTIFYING A DIALYZER APPARATUS OR A COMPONENT THEREOF, AND SENSOR DEVICE WHICH CAN BE USED FOR THIS PURPOSE - A system for acquiring or measuring information relating to a state of dialysance, identifying a dialyzer apparatus, or identifying a membrane filter device during the operation of the dialyzer apparatus in a dialysis treatment of a patient. The dialyzer apparatus includes a housing having an internal volume portion and a membrane filter device arranged within the internal volume portion. The housing allows transmission of radiation. A sensor device connected to the housing of the dialyzer apparatus includes a signal receiving device designed to receive a radiation signal from the housing, the signal characteristic of the state or the identification of the dialyzer apparatus or of the membrane filter unit of the dialyzer apparatus. | 2016-02-25 |
20160051743 | RE-USE OF A HEMODIALYSIS CARTRIDGE - The present invention provides a hemodialysis machine comprising a removably mountable cartridge having at least one inlet and at least one outlet, the cartridge defining a fluid pathway between said at least one inlet and said at least one outlet, a sanitisation device having an inlet and an outlet, a conduit connected between an outlet of the cartridge and the inlet of the sanitisation device and, a conduit connected between the outlet of the sanitisation device and an inlet of the cartridge. | 2016-02-25 |
20160051744 | PARALLEL PROCESSING OF FLUID COMPONENTS - A kit for blood component processing comprising a fluid circuit into which blood is drawn, wherein the fluid circuit comprises a plurality of pathways; wherein the first pathway is configured to receive blood drawn from a blood source and leads to a separation device, wherein the separation device is configured to separate the blood into components; wherein the second pathway is configured to receive a first component from the separation device and transport at least a portion of the first component to a first processing device, wherein the first processing device may alter the first component to produce a first output; and wherein the third pathway is configured to receive a second component from the separation device and transport at least a portion of the second component to a second processing device, wherein the second processing device may alter the second component to produce a second output. | 2016-02-25 |
20160051745 | Solid-Body Catheter Including Lateral Distal Openings - A catheter for vascular insertion, including a catheter body defining a first lumen and a second lumen, and including a distal region. The distal region includes an atraumatic nose portion defining a first distal opening in fluid communication with the first lumen, and a second distal opening in fluid communication with the second lumen. The distal region also includes a first lateral opening defined by the catheter body and in fluid communication with the first lumen, and a second lateral opening defined by the catheter body and in fluid communication with the second lumen. One or both of the first and second lateral openings may be defined by an angle cross-cut through an outer perimeter of the catheter body. | 2016-02-25 |